Armata Pharmaceuticals, Inc.
ARMP
$1.91
-$0.10-4.98%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -49.17% | -19.18% | 142.69% | -- | 21.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -49.17% | -19.18% | 142.69% | -- | 21.36% |
| Cost of Revenue | -32.27% | 2.76% | 124.31% | 2.62% | -16.53% |
| Gross Profit | 29.96% | -3.83% | 145.14% | -16.43% | 19.96% |
| SG&A Expenses | 2.36% | 4.53% | -9.46% | 46.34% | 25.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.44% | 6.01% | 10.10% | 12.30% | -7.81% |
| Operating Income | 19.92% | -10.02% | 5.61% | -23.73% | 9.85% |
| Income Before Tax | 73.90% | 113.10% | 82.41% | 353.34% | -72.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 73.90% | 113.10% | 82.41% | 353.34% | -72.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.90% | 113.10% | 82.41% | 353.34% | -72.68% |
| EBIT | 19.92% | -10.02% | 5.61% | -23.73% | 9.85% |
| EBITDA | 21.16% | -9.40% | 6.64% | -23.38% | 10.84% |
| EPS Basic | 73.94% | 113.08% | 82.46% | 352.80% | -72.29% |
| Normalized Basic EPS | 2.31% | -24.60% | -7.70% | -49.97% | -5.65% |
| EPS Diluted | 71.51% | 4.67% | 82.46% | -45.96% | -72.29% |
| Normalized Diluted EPS | 40.58% | 23.71% | -7.70% | -45.99% | -5.65% |
| Average Basic Shares Outstanding | 0.17% | 0.23% | 0.26% | 0.24% | 0.22% |
| Average Diluted Shares Outstanding | 64.65% | 63.66% | 0.26% | 3.01% | 0.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |